nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—Obstructive airways disorder—Methotrexate—esophageal cancer	0.0277	0.0361	CcSEcCtD
Lorazepam—Slurred speech—Cisplatin—esophageal cancer	0.0256	0.0334	CcSEcCtD
Lorazepam—Pericardial effusion—Capecitabine—esophageal cancer	0.0206	0.0268	CcSEcCtD
Lorazepam—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.0197	0.0257	CcSEcCtD
Lorazepam—Chlorthalidone—CA1—esophageal cancer	0.0172	0.277	CrCbGaD
Lorazepam—Pneumothorax—Capecitabine—esophageal cancer	0.0169	0.0221	CcSEcCtD
Lorazepam—Balance disorder—Capecitabine—esophageal cancer	0.0154	0.0201	CcSEcCtD
Lorazepam—Pericardial effusion—Methotrexate—esophageal cancer	0.0153	0.02	CcSEcCtD
Lorazepam—UGT2B15—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.0145	0.0908	CbGpPWpGaD
Lorazepam—Myoclonus—Capecitabine—esophageal cancer	0.014	0.0183	CcSEcCtD
Lorazepam—Infection—Carboplatin—esophageal cancer	0.0138	0.018	CcSEcCtD
Lorazepam—Liver injury—Cisplatin—esophageal cancer	0.0136	0.0177	CcSEcCtD
Lorazepam—Chlorthalidone—CA2—esophageal cancer	0.0131	0.21	CrCbGaD
Lorazepam—Dysarthria—Cisplatin—esophageal cancer	0.0121	0.0158	CcSEcCtD
Lorazepam—Pain—Carboplatin—esophageal cancer	0.0119	0.0155	CcSEcCtD
Lorazepam—UGT2B15—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.0116	0.0732	CbGpPWpGaD
Lorazepam—Hepatocellular injury—Cisplatin—esophageal cancer	0.0114	0.0149	CcSEcCtD
Lorazepam—Coagulopathy—Capecitabine—esophageal cancer	0.0108	0.0141	CcSEcCtD
Lorazepam—Memory impairment—Capecitabine—esophageal cancer	0.0107	0.014	CcSEcCtD
Lorazepam—Injection site pain—Capecitabine—esophageal cancer	0.0103	0.0135	CcSEcCtD
Lorazepam—Hypoxia—Methotrexate—esophageal cancer	0.00988	0.0129	CcSEcCtD
Lorazepam—Paralysis—Methotrexate—esophageal cancer	0.00904	0.0118	CcSEcCtD
Lorazepam—Dysarthria—Capecitabine—esophageal cancer	0.00892	0.0116	CcSEcCtD
Lorazepam—Amnesia—Cisplatin—esophageal cancer	0.00884	0.0115	CcSEcCtD
Lorazepam—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00843	0.011	CcSEcCtD
Lorazepam—Stupor—Methotrexate—esophageal cancer	0.00841	0.011	CcSEcCtD
Lorazepam—Injection site reaction—Capecitabine—esophageal cancer	0.00838	0.0109	CcSEcCtD
Lorazepam—Hyponatraemia—Cisplatin—esophageal cancer	0.00834	0.0109	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0083	0.0108	CcSEcCtD
Lorazepam—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00814	0.0106	CcSEcCtD
Lorazepam—Urinary incontinence—Capecitabine—esophageal cancer	0.00814	0.0106	CcSEcCtD
Lorazepam—Irritability—Cisplatin—esophageal cancer	0.00793	0.0103	CcSEcCtD
Lorazepam—Apnoea—Methotrexate—esophageal cancer	0.00741	0.00966	CcSEcCtD
Lorazepam—Mental disability—Capecitabine—esophageal cancer	0.00732	0.00954	CcSEcCtD
Lorazepam—Sleep disorder—Capecitabine—esophageal cancer	0.00707	0.00922	CcSEcCtD
Lorazepam—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00704	0.00918	CcSEcCtD
Lorazepam—Pancytopenia—Cisplatin—esophageal cancer	0.00682	0.00889	CcSEcCtD
Lorazepam—Dysarthria—Methotrexate—esophageal cancer	0.00664	0.00866	CcSEcCtD
Lorazepam—Amnesia—Capecitabine—esophageal cancer	0.00652	0.0085	CcSEcCtD
Lorazepam—Respiratory failure—Methotrexate—esophageal cancer	0.00639	0.00834	CcSEcCtD
Lorazepam—Lethargy—Capecitabine—esophageal cancer	0.00625	0.00815	CcSEcCtD
Lorazepam—Hyponatraemia—Capecitabine—esophageal cancer	0.00615	0.00802	CcSEcCtD
Lorazepam—Cystitis noninfective—Methotrexate—esophageal cancer	0.00613	0.008	CcSEcCtD
Lorazepam—Osteoarthritis—Capecitabine—esophageal cancer	0.00612	0.00798	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00612	0.00798	CcSEcCtD
Lorazepam—Diplopia—Capecitabine—esophageal cancer	0.00612	0.00798	CcSEcCtD
Lorazepam—Cystitis—Methotrexate—esophageal cancer	0.00606	0.00791	CcSEcCtD
Lorazepam—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00606	0.00791	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—GSTO1—esophageal cancer	0.00599	0.0377	CbGpPWpGaD
Lorazepam—Bradycardia—Cisplatin—esophageal cancer	0.00585	0.00763	CcSEcCtD
Lorazepam—Irritability—Capecitabine—esophageal cancer	0.00584	0.00762	CcSEcCtD
Lorazepam—Cardiac arrest—Capecitabine—esophageal cancer	0.00582	0.00759	CcSEcCtD
Lorazepam—Ataxia—Capecitabine—esophageal cancer	0.00576	0.00751	CcSEcCtD
Lorazepam—Coma—Methotrexate—esophageal cancer	0.00574	0.00748	CcSEcCtD
Lorazepam—Bladder pain—Methotrexate—esophageal cancer	0.00568	0.0074	CcSEcCtD
Lorazepam—Liver function test abnormal—Capecitabine—esophageal cancer	0.00565	0.00737	CcSEcCtD
Lorazepam—Pulmonary oedema—Methotrexate—esophageal cancer	0.00559	0.00729	CcSEcCtD
Lorazepam—Visual impairment—Cisplatin—esophageal cancer	0.00554	0.00722	CcSEcCtD
Lorazepam—Arrhythmia—Cisplatin—esophageal cancer	0.00513	0.00669	CcSEcCtD
Lorazepam—Alopecia—Cisplatin—esophageal cancer	0.00508	0.00662	CcSEcCtD
Lorazepam—Pancytopenia—Capecitabine—esophageal cancer	0.00502	0.00655	CcSEcCtD
Lorazepam—Erythema—Cisplatin—esophageal cancer	0.005	0.00652	CcSEcCtD
Lorazepam—Visual disturbance—Methotrexate—esophageal cancer	0.00481	0.00627	CcSEcCtD
Lorazepam—Vision blurred—Cisplatin—esophageal cancer	0.00471	0.00615	CcSEcCtD
Lorazepam—Tremor—Cisplatin—esophageal cancer	0.00469	0.00611	CcSEcCtD
Lorazepam—Lethargy—Methotrexate—esophageal cancer	0.00465	0.00606	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—GSTT1—esophageal cancer	0.00465	0.0292	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—ADH7—esophageal cancer	0.00463	0.0291	CbGpPWpGaD
Lorazepam—Diclofenac—PTGS1—esophageal cancer	0.00462	0.0742	CrCbGaD
Lorazepam—Jaundice—Capecitabine—esophageal cancer	0.0046	0.006	CcSEcCtD
Lorazepam—Osteoarthritis—Methotrexate—esophageal cancer	0.00456	0.00594	CcSEcCtD
Lorazepam—Agranulocytosis—Capecitabine—esophageal cancer	0.0044	0.00574	CcSEcCtD
Lorazepam—Irritability—Methotrexate—esophageal cancer	0.00435	0.00567	CcSEcCtD
Lorazepam—Convulsion—Cisplatin—esophageal cancer	0.00433	0.00565	CcSEcCtD
Lorazepam—Bradycardia—Capecitabine—esophageal cancer	0.00431	0.00562	CcSEcCtD
Lorazepam—Ataxia—Methotrexate—esophageal cancer	0.00428	0.00559	CcSEcCtD
Lorazepam—Liver function test abnormal—Methotrexate—esophageal cancer	0.00421	0.00549	CcSEcCtD
Lorazepam—Clozapine—CYP1B1—esophageal cancer	0.00412	0.0663	CrCbGaD
Lorazepam—Visual impairment—Capecitabine—esophageal cancer	0.00408	0.00532	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—ADH1B—esophageal cancer	0.00406	0.0255	CbGpPWpGaD
Lorazepam—Infection—Cisplatin—esophageal cancer	0.00405	0.00529	CcSEcCtD
Lorazepam—Flurazepam—CYP2A6—esophageal cancer	0.00405	0.0651	CrCbGaD
Lorazepam—Thrombocytopenia—Cisplatin—esophageal cancer	0.004	0.00521	CcSEcCtD
Lorazepam—Tachycardia—Cisplatin—esophageal cancer	0.00398	0.0052	CcSEcCtD
Lorazepam—Hypotension—Cisplatin—esophageal cancer	0.00381	0.00497	CcSEcCtD
Lorazepam—Chills—Capecitabine—esophageal cancer	0.0038	0.00496	CcSEcCtD
Lorazepam—Arrhythmia—Capecitabine—esophageal cancer	0.00378	0.00493	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—CYP26A1—esophageal cancer	0.00377	0.0237	CbGpPWpGaD
Lorazepam—Alopecia—Capecitabine—esophageal cancer	0.00374	0.00488	CcSEcCtD
Lorazepam—Pancytopenia—Methotrexate—esophageal cancer	0.00374	0.00488	CcSEcCtD
Lorazepam—Erythema—Capecitabine—esophageal cancer	0.00369	0.00481	CcSEcCtD
Lorazepam—Erectile dysfunction—Methotrexate—esophageal cancer	0.00363	0.00473	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00352	0.0046	CcSEcCtD
Lorazepam—Drowsiness—Methotrexate—esophageal cancer	0.00351	0.00458	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—GSTO1—esophageal cancer	0.00351	0.022	CbGpPWpGaD
Lorazepam—Pain—Cisplatin—esophageal cancer	0.00349	0.00455	CcSEcCtD
Lorazepam—Vision blurred—Capecitabine—esophageal cancer	0.00347	0.00453	CcSEcCtD
Lorazepam—Tremor—Capecitabine—esophageal cancer	0.00345	0.0045	CcSEcCtD
Lorazepam—Feeling abnormal—Cisplatin—esophageal cancer	0.00336	0.00439	CcSEcCtD
Lorazepam—Vertigo—Capecitabine—esophageal cancer	0.00331	0.00432	CcSEcCtD
Lorazepam—Agranulocytosis—Methotrexate—esophageal cancer	0.00328	0.00427	CcSEcCtD
Lorazepam—GABRB3—Orphan transporters—SLC10A2—esophageal cancer	0.00321	0.0202	CbGpPWpGaD
Lorazepam—Hypertension—Capecitabine—esophageal cancer	0.00318	0.00415	CcSEcCtD
Lorazepam—Clozapine—CYP2A6—esophageal cancer	0.00318	0.0511	CrCbGaD
Lorazepam—GABRG2—Orphan transporters—SLC10A2—esophageal cancer	0.00315	0.0198	CbGpPWpGaD
Lorazepam—GABRB3—GABA receptor activation—GNG7—esophageal cancer	0.00308	0.0194	CbGpPWpGaD
Lorazepam—Dry mouth—Capecitabine—esophageal cancer	0.00307	0.004	CcSEcCtD
Lorazepam—Visual impairment—Methotrexate—esophageal cancer	0.00304	0.00396	CcSEcCtD
Lorazepam—Confusional state—Capecitabine—esophageal cancer	0.00303	0.00396	CcSEcCtD
Lorazepam—GABRG2—GABA receptor activation—GNG7—esophageal cancer	0.00303	0.019	CbGpPWpGaD
Lorazepam—Hypersensitivity—Cisplatin—esophageal cancer	0.00301	0.00392	CcSEcCtD
Lorazepam—Infection—Capecitabine—esophageal cancer	0.00299	0.0039	CcSEcCtD
Lorazepam—Thrombocytopenia—Capecitabine—esophageal cancer	0.00295	0.00384	CcSEcCtD
Lorazepam—Tachycardia—Capecitabine—esophageal cancer	0.00294	0.00383	CcSEcCtD
Lorazepam—Asthenia—Cisplatin—esophageal cancer	0.00293	0.00382	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—ALDH2—esophageal cancer	0.00286	0.018	CbGpPWpGaD
Lorazepam—Chills—Methotrexate—esophageal cancer	0.00283	0.00369	CcSEcCtD
Lorazepam—Hypotension—Capecitabine—esophageal cancer	0.00281	0.00367	CcSEcCtD
Lorazepam—Alopecia—Methotrexate—esophageal cancer	0.00279	0.00363	CcSEcCtD
Lorazepam—GABRA1—Orphan transporters—SLC10A2—esophageal cancer	0.00275	0.0173	CbGpPWpGaD
Lorazepam—Erythema—Methotrexate—esophageal cancer	0.00274	0.00358	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—GSTT1—esophageal cancer	0.00272	0.0171	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—CYP2A6—esophageal cancer	0.00269	0.0169	CbGpPWpGaD
Lorazepam—GABRA1—GABA receptor activation—GNG7—esophageal cancer	0.00265	0.0166	CbGpPWpGaD
Lorazepam—Diclofenac—PTGS2—esophageal cancer	0.00264	0.0424	CrCbGaD
Lorazepam—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0026	0.00339	CcSEcCtD
Lorazepam—Vomiting—Cisplatin—esophageal cancer	0.0026	0.00338	CcSEcCtD
Lorazepam—Fatigue—Capecitabine—esophageal cancer	0.00259	0.00338	CcSEcCtD
Lorazepam—Vision blurred—Methotrexate—esophageal cancer	0.00259	0.00337	CcSEcCtD
Lorazepam—Rash—Cisplatin—esophageal cancer	0.00257	0.00336	CcSEcCtD
Lorazepam—Pain—Capecitabine—esophageal cancer	0.00257	0.00336	CcSEcCtD
Lorazepam—Constipation—Capecitabine—esophageal cancer	0.00257	0.00336	CcSEcCtD
Lorazepam—Dermatitis—Cisplatin—esophageal cancer	0.00257	0.00335	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—PTGS1—esophageal cancer	0.00255	0.016	CbGpPWpGaD
Lorazepam—Feeling abnormal—Capecitabine—esophageal cancer	0.00248	0.00323	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—CRTC1—esophageal cancer	0.00247	0.0155	CbGpPWpGaD
Lorazepam—Diazepam—PTGS1—esophageal cancer	0.00247	0.0396	CrCbGaD
Lorazepam—Vertigo—Methotrexate—esophageal cancer	0.00247	0.00322	CcSEcCtD
Lorazepam—Nausea—Cisplatin—esophageal cancer	0.00242	0.00316	CcSEcCtD
Lorazepam—Convulsion—Methotrexate—esophageal cancer	0.00238	0.0031	CcSEcCtD
Lorazepam—Confusional state—Methotrexate—esophageal cancer	0.00226	0.00295	CcSEcCtD
Lorazepam—TSPO—exocrine gland—esophageal cancer	0.00226	0.189	CbGeAlD
Lorazepam—Diclofenac—ABCB1—esophageal cancer	0.00225	0.0361	CrCbGaD
Lorazepam—Infection—Methotrexate—esophageal cancer	0.00223	0.0029	CcSEcCtD
Lorazepam—Hypersensitivity—Capecitabine—esophageal cancer	0.00222	0.00289	CcSEcCtD
Lorazepam—Thrombocytopenia—Methotrexate—esophageal cancer	0.00219	0.00286	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—CYP1B1—esophageal cancer	0.00217	0.0136	CbGpPWpGaD
Lorazepam—Asthenia—Capecitabine—esophageal cancer	0.00216	0.00282	CcSEcCtD
Lorazepam—GABRB3—Ion channel transport—ATP1B2—esophageal cancer	0.00212	0.0133	CbGpPWpGaD
Lorazepam—Hypotension—Methotrexate—esophageal cancer	0.00209	0.00273	CcSEcCtD
Lorazepam—UGT2B15—digestive system—esophageal cancer	0.00208	0.175	CbGeAlD
Lorazepam—GABRG2—Ion channel transport—ATP1B2—esophageal cancer	0.00208	0.0131	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—CYP19A1—esophageal cancer	0.00204	0.0128	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00199	0.0125	CbGpPWpGaD
Lorazepam—Somnolence—Methotrexate—esophageal cancer	0.00199	0.0026	CcSEcCtD
Lorazepam—Dizziness—Capecitabine—esophageal cancer	0.00199	0.00259	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00193	0.00252	CcSEcCtD
Lorazepam—Fatigue—Methotrexate—esophageal cancer	0.00193	0.00252	CcSEcCtD
Lorazepam—Pain—Methotrexate—esophageal cancer	0.00192	0.0025	CcSEcCtD
Lorazepam—Vomiting—Capecitabine—esophageal cancer	0.00191	0.00249	CcSEcCtD
Lorazepam—Rash—Capecitabine—esophageal cancer	0.0019	0.00247	CcSEcCtD
Lorazepam—Dermatitis—Capecitabine—esophageal cancer	0.0019	0.00247	CcSEcCtD
Lorazepam—Headache—Capecitabine—esophageal cancer	0.00188	0.00246	CcSEcCtD
Lorazepam—Feeling abnormal—Methotrexate—esophageal cancer	0.00185	0.00241	CcSEcCtD
Lorazepam—GABRB3—Ion channel transport—ATP4A—esophageal cancer	0.00183	0.0115	CbGpPWpGaD
Lorazepam—GABRA1—Ion channel transport—ATP1B2—esophageal cancer	0.00182	0.0114	CbGpPWpGaD
Lorazepam—GABRG2—Ion channel transport—ATP4A—esophageal cancer	0.0018	0.0113	CbGpPWpGaD
Lorazepam—Nausea—Capecitabine—esophageal cancer	0.00179	0.00233	CcSEcCtD
Lorazepam—Nitrazepam—ABCB1—esophageal cancer	0.0017	0.0273	CrCbGaD
Lorazepam—Hypersensitivity—Methotrexate—esophageal cancer	0.00165	0.00215	CcSEcCtD
Lorazepam—Chlorprothixene—ABCB1—esophageal cancer	0.00162	0.026	CrCbGaD
Lorazepam—Asthenia—Methotrexate—esophageal cancer	0.00161	0.0021	CcSEcCtD
Lorazepam—GABRA1—Ion channel transport—ATP4A—esophageal cancer	0.00157	0.0099	CbGpPWpGaD
Lorazepam—Flurazepam—ABCB1—esophageal cancer	0.00151	0.0243	CrCbGaD
Lorazepam—Dizziness—Methotrexate—esophageal cancer	0.00148	0.00193	CcSEcCtD
Lorazepam—GABRB3—BDNF signaling pathway—CFL1—esophageal cancer	0.00147	0.00924	CbGpPWpGaD
Lorazepam—TSPO—neck—esophageal cancer	0.00144	0.121	CbGeAlD
Lorazepam—Vomiting—Methotrexate—esophageal cancer	0.00142	0.00186	CcSEcCtD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00142	0.00891	CbGpPWpGaD
Lorazepam—Rash—Methotrexate—esophageal cancer	0.00141	0.00184	CcSEcCtD
Lorazepam—Dermatitis—Methotrexate—esophageal cancer	0.00141	0.00184	CcSEcCtD
Lorazepam—Headache—Methotrexate—esophageal cancer	0.0014	0.00183	CcSEcCtD
Lorazepam—Midazolam—ABCB1—esophageal cancer	0.0014	0.0225	CrCbGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00139	0.00875	CbGpPWpGaD
Lorazepam—Nausea—Methotrexate—esophageal cancer	0.00133	0.00174	CcSEcCtD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00128	0.00806	CbGpPWpGaD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00122	0.00765	CbGpPWpGaD
Lorazepam—Diazepam—ABCB1—esophageal cancer	0.0012	0.0193	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00118	0.00744	CbGpPWpGaD
Lorazepam—Clozapine—ABCB1—esophageal cancer	0.00118	0.019	CrCbGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00114	0.00719	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—BLVRB—esophageal cancer	0.00109	0.00688	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—SLC52A3—esophageal cancer	0.00109	0.00688	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00107	0.0067	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00105	0.00658	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000999	0.00628	CbGpPWpGaD
Lorazepam—TSPO—epithelium—esophageal cancer	0.000981	0.0824	CbGeAlD
Lorazepam—GABRG2—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000981	0.00616	CbGpPWpGaD
Lorazepam—TSPO—bronchus—esophageal cancer	0.000967	0.0812	CbGeAlD
Lorazepam—TSPO—smooth muscle tissue—esophageal cancer	0.000946	0.0794	CbGeAlD
Lorazepam—UGT2B15—Metabolism—SLC10A2—esophageal cancer	0.00093	0.00585	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CA1—esophageal cancer	0.00093	0.00585	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000915	0.00575	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.000889	0.00559	CbGpPWpGaD
Lorazepam—TSPO—trachea—esophageal cancer	0.000868	0.0729	CbGeAlD
Lorazepam—GABRA1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000857	0.00539	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CA2—esophageal cancer	0.000851	0.00535	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—GNG7—esophageal cancer	0.000817	0.00513	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—GNG7—esophageal cancer	0.000802	0.00504	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PLCE1—esophageal cancer	0.000791	0.00497	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ADH7—esophageal cancer	0.000791	0.00497	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000783	0.00492	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000769	0.00483	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—ALDH2—esophageal cancer	0.000765	0.00481	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—ALDH2—esophageal cancer	0.000752	0.00472	CbGpPWpGaD
Lorazepam—TSPO—digestive system—esophageal cancer	0.000747	0.0627	CbGeAlD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000737	0.00463	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000723	0.00455	CbGpPWpGaD
Lorazepam—GABRB3—Orphan transporters—CREBBP—esophageal cancer	0.000703	0.00442	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—GNG7—esophageal cancer	0.000701	0.00441	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000698	0.00439	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ADH1B—esophageal cancer	0.000694	0.00436	CbGpPWpGaD
Lorazepam—GABRG2—Orphan transporters—CREBBP—esophageal cancer	0.00069	0.00434	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000686	0.00431	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000672	0.00423	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000666	0.00419	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TYMP—esophageal cancer	0.000663	0.00417	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—ALDH2—esophageal cancer	0.000657	0.00413	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000654	0.00411	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP26A1—esophageal cancer	0.000645	0.00405	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000639	0.00401	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000639	0.00401	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000632	0.00397	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALOX15—esophageal cancer	0.000628	0.00395	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000627	0.00394	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000627	0.00394	CbGpPWpGaD
Lorazepam—TSPO—lung—esophageal cancer	0.000624	0.0524	CbGeAlD
Lorazepam—GABRA1—Orphan transporters—CREBBP—esophageal cancer	0.000603	0.00379	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—TPI1—esophageal cancer	0.0006	0.00377	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTO1—esophageal cancer	0.0006	0.00377	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000599	0.00377	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALDOB—esophageal cancer	0.000575	0.00361	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000572	0.00359	CbGpPWpGaD
Lorazepam—GABRB3—lung—esophageal cancer	0.000566	0.0475	CbGeAlD
Lorazepam—UGT2B15—Metabolism—GAPDH—esophageal cancer	0.000553	0.00348	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CRABP1—esophageal cancer	0.000548	0.00345	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000548	0.00344	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000548	0.00344	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000534	0.00336	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GNG7—esophageal cancer	0.000522	0.00328	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALDH2—esophageal cancer	0.000489	0.00307	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000484	0.00304	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000475	0.00299	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTT1—esophageal cancer	0.000465	0.00292	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP2A6—esophageal cancer	0.000459	0.00289	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000439	0.00276	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000436	0.00274	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PTGS1—esophageal cancer	0.000436	0.00274	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ENO1—esophageal cancer	0.000436	0.00274	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000431	0.00271	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PSME2—esophageal cancer	0.000429	0.0027	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PSME1—esophageal cancer	0.000429	0.0027	CbGpPWpGaD
Lorazepam—TSPO—lymph node—esophageal cancer	0.000426	0.0358	CbGeAlD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000415	0.00261	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000377	0.00237	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP1B1—esophageal cancer	0.00037	0.00233	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP19A1—esophageal cancer	0.000348	0.00219	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HMOX1—esophageal cancer	0.000318	0.002	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ABCB1—esophageal cancer	0.000305	0.00192	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000297	0.00187	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000268	0.00168	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000263	0.00165	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000257	0.00161	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000252	0.00158	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00023	0.00144	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00022	0.00139	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CREBBP—esophageal cancer	0.000204	0.00128	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NOS3—esophageal cancer	0.000183	0.00115	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000172	0.00108	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000169	0.00106	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PTGS2—esophageal cancer	0.000167	0.00105	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000147	0.000926	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—EP300—esophageal cancer	0.000139	0.000873	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—PIK3CA—esophageal cancer	0.000103	0.000645	CbGpPWpGaD
